P3 Health Partners Inc. Quarterly report [Sections 13 or 15(d)]

Quarterly report [Sections 13 or 15(d)]

Net Loss per Share (Tables)

Net Loss per Share (Tables)

3 Months Ended

Mar. 31, 2026

Schedule of Computation of Basic and Diluted Net Loss Per Share

The following table provides the computation of basic and diluted net income (loss) per share:


	Three Months Ended March 31,
	2026		2025
	(in thousands, except per share data)
Numerator–basic:
Net income (loss) attributable to Class A common stockholders–basic	$	1,223	$	(20,480)
Numerator–diluted:
Net income (loss) attributable to Class A common stockholders–basic	$	1,223	$	(20,480)
Effect of dilutive securities:
Net income (loss) attributable to Class V common stockholders	1,457		—
Liability-classified warrants	—		—
Net income (loss) attributable to Class A common stockholders–diluted	$	2,680	$	(20,480)
Denominator–basic:
Weighted average Class A common shares outstanding–basic	3,288		3,260
Net income (loss) per share attributable to Class A common stockholders–basic	$	0.37	$	(6.28)
Denominator–diluted:
Weighted average Class A common shares outstanding–basic	3,288		3,260
Weighted average effect of dilutive securities:
Shares of Class V common stock	3,919		—
Restricted stock units	3		—
Equity-classified warrants	1,207		—
Liability-classified warrants	—		—
Weighted average shares outstanding–diluted	8,417		3,260
Net income (loss) per share attributable to Class A common stockholders–diluted	$	0.32	$	(6.28)

Schedule of potential dilutive securities excluded from the computation of diluted net loss per share their effect would have been anti-dilutive

The following table presents potentially dilutive securities excluded from the computation of diluted net income (loss) per share for the periods presented because their effect would have been anti-dilutive.


	Three Months Ended March 31,
	2026	2025
	(in thousands)
Stock warrants (1)	8,492	6,358
Stock options (1)	450	433
Restricted stock units (1)	165	141

Shares of Class V common stock (2)	—	3,919
Total	9,107	10,851

__________________

(1)Represents the number of instruments outstanding at the end of the period. Application of the treasury stock method would reduce this amount if they had a dilutive effect and were included in the computation of diluted net income (loss) per share.

(2)Shares of Class V common stock at the end of the period are considered antidilutive shares of Class A common stock under application of the if-converted method in 2025.